FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>KELER TIBOR</u>				2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Executive VP & CSO					
(Last) (First) (Middle) C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD			0	3. Date of Earliest Transaction (Month/Day/Year) 06/15/2017												
(Street)		-	08827	⁴ 	. If Am	endment,	Date of	f Original Fil	ed (M	Ionth/Day	//Year)	6. In Line)	Form fil	ed by One F	Filing (Check Aptended of the Check Aptended of the Check Appendix	on
(City)	(S	state)	(Zip)													
			ble I - Non-D	erivati	ive S	ecuritie	s Acc	quired, D	ispo	osed of	f, or Ber	neficially	Owned			
1. Title of Security (Instr. 3) 2. Transplate (Month/I			te	2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired (A Disposed Of (D) (Instr. 3, 8)		d (A) or r. 3, 4 and 5	Beneficial Owned Fo	s Form ally (D) of ollowing (I) (II	6. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership				
							Code V	, A	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 ar			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	Conversion Date Execution or Exercise (Month/Day/Year) if any		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)	
				Code	v	(A)		Date Exercisable	Exp Dat	piration te	Title	Amount or Number of Shares		(Instr. 4)	11(2)	
Incentive Stock Option (right to	\$2.32	06/15/2017		A		162,000		06/15/2018 ⁽²⁾	06/:	/15/2027	Common Stock	162,000	\$0.00	162,000) D	

Explanation of Responses:

- $1. \ Represents option \ granted \ by \ the \ Issuer \ pursuant \ to \ its \ 2008 \ Stock \ Option \ and \ Incentive \ Plan.$
- $2.\,25\%\ vest\ on\ June\ 15,\ 2018\ and\ the\ remainder\ vest\ quarterly\ (in\ equal\ amounts)\ over\ the\ subsequent\ 12\ quarters.$

/s/ Avery W. Catlin, attorney in fact for Tibor Keler

06/16/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.